Otulfi®▼

(ustekinumab)

For healthcare professionals only. This content contains promotional and brand information. 

Scroll down for Otulfi prescribing information and further product details. For adverse event reporting see bottom of webpage. 

 

Otulfi is available in the following presentations:

  • Otulfi 45mg solution for injection in pre-filled pen
  • Otulfi 45mg solution for injection in pre-filled syringe
  • Otulfi 45mg solution for injection
  • Otulfi 90mg solution for injection in pre-filled pen
  • Otulfi 90mg solution for injection in pre-filled syringe
  • Otulfi 130mg concentrate for solution for infusion

The SmPC and Patient Leaflets are located on the electronic medicines compendium (emc). Note: by clicking the link you will leave the Fresenius Kabi GB website and be directed to the electronic medicines compendium website.

Please note that product images are for illustrative purposes only and labelling on products may appear differently.

Product Image Sizing FK website - otulfi
Filename
Otulfi Prescribing Information UK Sept 2026.pdf
Size
141 KB
Format
pdf
Otulfi Prescribing Information

Details

Otulfi is licensed in the following disease areas. Please consult the individual SmPCs for full details of indications and prescribing information. Otulfi treatment should be initiated by healthcare professionals and supervised by specialist physicians experienced in the diagnosis and treatment of conditions for which Otulfi is indicated.

Otulfi 45mg solution for injection in a pre-filled pen:
  • Plaque psoriasis (adults)
  • Psoriatic arthritis (PsA) (adults)
  • Crohn's Disease (adults)
  • Ulcerative Colitis (adults)
Otulfi 45mg solution for injection in a pre-filled syringe:
  • Plaque psoriasis (adults and paediatrics)
  • Psoriatic arthritis (adults)
  • Crohn's Disease (adults and paediatrics)
  • Ulcerative colitis (adults)
Otulfi 45mg solution for injection:
  • Plaque psoriasis (adults and paediatrics)
  • Psoriatic arthritis (adults)
  • Crohn's Disease (adults and paediatrics)
  • Ulcerative colitis (adults)
Otulfi 90mg solution for injection in a pre-filled pen:
  • Plaque psoriasis (adults)
  • Psoriatic arthritis (PsA) (adults)
  • Crohn's Disease (adults)
  • Ulcerative Colitis (adults)
Otulfi 90mg solution for injection in a pre-filled syringe:
  • Plaque psoriasis (adults and paediatrics)
  • Psoriatic arthritis (adults)
  • Crohn's Disease (adults and paediatrics)
  • Ulcerative colitis (adults)
Otulfi 130mg concentrate for solution for infusion:
  • Crohn's Disease (adults and paediatrics)
  • Ulcerative colitis (adults)

Product Presentation: Order codes: 
Otulfi 45mg vialF02102A12
Otulfi 130mg vialF02102B11
Otulfi 45mg PFS (pre filled syringe) F02102A12
Otulfi 90mg PFS (pre filled syringe)F02102B12
Otulfi 45mg (pre filled pen)F02102A13
Otulfi 90mg (pre filled pen)F02102B13
Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk  Adverse events should also be reported to Fresenius Kabi Ltd. Cestrian Court, Eastgate Way, Manor Park, Runcorn, Cheshire, WA7 1NT Tel +44 (0)800 090 2513. Email: pharmacovigilance.gb@fresenius-kabi.com

GB-USTE-2600001 September 2026

By entering the Healthcare Professional Area you are confirming you are a GB Healthcare Professional. This area contains promotional information. If you are not a Healthcare Professional you will be directed to the Fresenius Kabi GB Corporate website.

GB-NP-2400163 October 2024

I am a Healthcare Professional I am not a Healthcare Professional